Navigation Links
InterMune to Divest Actimmune® (Interferon Gamma-1b)
Date:5/21/2012

scribing information regarding Actimmune, including the product's safety profile, by visiting www.actimmune.com.

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to our expectations of the uses of the capital from the divesture of Actimmune for investing in the registration and commercialization of Esbriet and the cash infusion to execute our Vision 2015 strategic plan.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from any results expressed or implied by such forward-looking statements. For example, there are risks associated with the closing of the transaction for the divesture of Actimmune, including the ability o
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Zacks.com announces the list of stocks featured in ... discuss the latest news and events impacting stocks and the ... (Nasdaq: BIIB - Free Report ), Gilead (Nasdaq: ... - Free Report ), AbbVie (NYSE: ABBV - Free ... ). Today, Zacks is promoting its ,Buy, stock ...
(Date:7/31/2014)... July 31, 2014 Vermillion, Inc. (NASDAQ: VRML), a ... will hold a conference call on Thursday, August 14, 2014, ... second quarter ended June 30, 2014. Financial results will be ... Vermillion,s Chairman, President and CEO James LaFrance ... period. Date: Thursday, August 14, 2014 Time: 4:30 ...
(Date:7/31/2014)... , July 31, 2014 TB Alliance, ... developing better, faster and affordable treatments, announced the ... Vice President, External Affairs. Mr. Brock comes to ... of Major Donor Relations for WWF International (formerly ... role, Mr. Brock will guide the TB Alliance,s ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2
... 1 The Michael J. Fox Foundation for ... to $6.5 million in total funding available under ... solutions to some of the most difficult hurdles ... PD.The Critical Challenges funding opportunities focus research efforts ...
... 31 Successful and seamless completion of clinical trial ... market research, an effective recruitment strategy, and project management ... Liz Moench notes: "This is achievable when clinical trial ... adds, "We had great team chemistry with the study ...
Cached Medicine Technology:Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinson's Disease 2Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinson's Disease 3Major Restless Legs Study Completes Enrollment With Support From MediciGlobal 2
(Date:7/31/2014)... 31, 2014 The 2013 edition ... about chemical listings, appellate decisions, litigation and settlement ... affect compliance with California's Proposition 65. , The ... law, regulations, history and trends impacting California's Proposition ... installment of the series which adds approximately 200 ...
(Date:7/31/2014)... (August 1, 2014) If you have asthma, you may ... to help you recognize and respond to changes and understand ... you,re in the green zone, you,re doing well, yellow means ... means you require urgent care. New guidelines are now available ... zone, back into green and away from the red zone. ...
(Date:7/31/2014)... Developer Jamestown, L.P., has been using ... City Market project in Atlanta’s Old Fourth Ward, which ... building into best-in-class office, housing, and retail spaces. As ... with their construction webcam service to assess how it ... construction camera for monitoring and documentation purposes, ...
(Date:7/31/2014)... Hoping to attract new customers who are ... , NutriGold is ready to ship out free samples of ... advantage of this offer fast and easy: http://www.nutrigold.com/Free-Samples ... at NutriGold, "We know that every time customers purchase one ... precious asset: their own health or the health of a ...
(Date:7/31/2014)... has announced that they are now offering a new ... Review of Sexual Satisfaction . The course is ... Clinical and Health Psychology. , This CE course has ... accurate information about sexual satisfaction so that healthcare professionals ... provides a systematic review of 197 research publications in ...
Breaking Medicine News(10 mins):Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:NutriGold Launches Product Samples Page for its Supplements 2Health News:NutriGold Launches Product Samples Page for its Supplements 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3
... ... with GFK Custom Research North America, selected Warady & Davis LLP, Certified Public Accountants ... Chicago based on its innovative internships, "W&D University" training program, flexible scheduling, great team ... ...
... Oct. 28 The Board of Directors of Healthcare Trust ... of October, November, and December 2009. These distributions will ... during such month and will equal a 7.25% annualized rate ... The payment date for each of the daily distributions for ...
... , DENVER, Oct. 28 Many medical practices are ... are making basic business mistakes, according to Andrew Graham, ... the top reasons practices struggle, said Graham. , ... needs to include goals for revenue generation, customer service, ...
... for the third quarter ended September 30, 2009. Financial highlights from continuing operations for the third quarter of 2009 compared to ... in millions, except per share amounts), ... ... ...
... supply and demand starting to close, U.S. officials say, ... reported Wednesday the addition of another million doses H1N1 ... 23.2 million doses. , "We know people are ... now," Janet Napolitano, secretary of the U.S. Department of ...
... Application provides ... ... Harvard Health Publications Division of Harvard Medical School has launched an iPhone application focused ... knowledge of the experts at Harvard Medical School along with its long-standing expertise in publishing ...
Cached Medicine News:Health News:Warady & Davis LLP Named One of 'Top 50 Employers for Generation Y Chicago' 2Health News:Warady & Davis LLP Named One of 'Top 50 Employers for Generation Y Chicago' 3Health News:Board of Directors Declares Cash Distributions 2Health News:The Top 10 Business Mistakes Made By Physician Practices 2Health News:Carriage Services Announces Third Quarter 2009 Results 2Health News:Carriage Services Announces Third Quarter 2009 Results 3Health News:Carriage Services Announces Third Quarter 2009 Results 4Health News:Carriage Services Announces Third Quarter 2009 Results 5Health News:Carriage Services Announces Third Quarter 2009 Results 6Health News:Carriage Services Announces Third Quarter 2009 Results 7Health News:Carriage Services Announces Third Quarter 2009 Results 8Health News:Carriage Services Announces Third Quarter 2009 Results 9Health News:Carriage Services Announces Third Quarter 2009 Results 10Health News:Carriage Services Announces Third Quarter 2009 Results 11Health News:Carriage Services Announces Third Quarter 2009 Results 12Health News:Carriage Services Announces Third Quarter 2009 Results 13Health News:Carriage Services Announces Third Quarter 2009 Results 14Health News:Carriage Services Announces Third Quarter 2009 Results 15Health News:Carriage Services Announces Third Quarter 2009 Results 16Health News:Carriage Services Announces Third Quarter 2009 Results 17Health News:Carriage Services Announces Third Quarter 2009 Results 18Health News:Carriage Services Announces Third Quarter 2009 Results 19Health News:Carriage Services Announces Third Quarter 2009 Results 20Health News:1 Million More Doses of Swine Flu Vaccine on Hand 2Health News:Harvard Health Publications Launches H1N1 Flu iPhone Application 2Health News:Harvard Health Publications Launches H1N1 Flu iPhone Application 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: